Investigational drug · Phase 2
YCT-529
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Male Contraception.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "YCT-529"
First trial start
2024
Sep 11, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "YCT-529", any sponsor or status.
Conditions studied
As listed on its trial records.
- Male Contraception
Approved drugs for the same conditions: Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "YCT-529" as an intervention, largest first.
YourChoice Therapeutics, Inc.Industry
NCT06542237 · 88 participants (planned) · Start Sep 11, 2024 · Primary completion Jul 31, 2026
Drug: YCT-529 · For: Male Contraception
Sites: Grafton, New Zealand
YourChoice Therapeutics, Inc.Industry
NCT06094283 · 16 participants · Start Dec 20, 2023 · Primary completion Jun 18, 2024
Drug: YCT-529; YCT-529 Placebo · For: Male Contraception
Sites: Nottingham, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Second-Generation Synthesis of the Male Contraceptive YCT-529.
Gantasala N, Cheryala N, Georg GI · J Org Chem 2026
- Author Correction: Safety and pharmacokinetics of the non-hormonal male contraceptive YCT-529.
Mannowetz N, McCallum SW, Sidhu S, et al. · Commun Med (Lond) 2026
- Syntheses of YCT-529: Net [3 + 2] Cycloaddition and One-Pot Bromination-Suzuki-Miyaura Coupling Strategies.
Dada R, Cheryala N, Georg GI · J Org Chem 2026
- From concept to the clinic: Retinoic acid receptor α antagonist YCT-529, an oral non-hormonal male contraceptive.
Taher N, Haque E, Georg GI · Andrology 2026
- [Male contraception-scientific foundations and contemporary progress].
Zitzmann M · Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2026
- Correction to "From Discovery to Clinical Trial: YCT-529, an Oral NonHormonal Male Contraceptive Targeting the Retinoic Acid Receptor Alpha".
Shi R, Al Noman MA, Mannowetz N, et al. · J Med Chem 2026
Also in development for Male Contraception
- NLS-133Phase 21 trial
Next Life Sciences · Male Contraception, Semen Volume, Sperm Motility
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.